Abstract
The Spike S/Basigin (BSG) interaction, validated in 2020, has since been called putative, postulated, and controversial. Two widely referenced articles have been largely responsible for this. The data presented here demonstrates that the exclusion of this interaction these articles purport to show is due to an inappropriate binding affinity reference value. Spike S/BSG binding avidity is admittedly weaker than that of RH5 (falciparum epitope)/BSG by oligomeric methods, but one cannot then exclude its existence by using a monomeric binding affinity value. Additional clinical and laboratory support for this Spike S/BSG interaction is presented, including the obesity paradox and thrombotic microangiopathy (TMA). Furthermore, BSG is up-regulated in those with comorbidities, something not considered in these two articles.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.